Investigating how Foxa2 influences nuclear receptor activation
Role of Foxa2 in ligand-dependent activation of nuclear receptors
This study is looking at a protein called Foxa2 to see how it helps control important processes in the body that can affect diseases like cancer and heart problems, with the goal of finding better and safer treatments for patients.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Pittsburgh at Pittsburgh NIH-funded |
| Lab location | 1 site (Pittsburgh, United States) |
| Project ID | NIH-11047348 on NIH RePORTER |
What this research studies
This research explores the role of Foxa2, a protein that may help activate nuclear receptors, which are important for regulating various metabolic processes and diseases like cancer and atherosclerosis. By examining how Foxa2 affects chromatin accessibility and receptor binding, the study aims to improve our understanding of how these receptors can be targeted for drug development. The approach involves analyzing changes in chromatin structure upon ligand activation, which could lead to more effective therapies with fewer side effects for patients. This research could ultimately provide insights into better treatment strategies for metabolic diseases and cancers.
Who could benefit from this research
Good fit: Ideal candidates for this research include individuals with metabolic diseases, atherosclerosis, or certain types of cancer.
Not a fit: Patients with conditions unrelated to metabolic processes or nuclear receptor activity may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to the development of more effective and safer drugs for metabolic diseases and cancers.
How similar studies have performed: Other research has shown promise in targeting nuclear receptors for drug development, indicating that this approach could lead to significant advancements.
Where this research is happening
Pittsburgh, United States
- University of Pittsburgh at Pittsburgh — Pittsburgh, United States (Active)
Researchers
- Principal investigator: Bochkis, Irina — University of Pittsburgh at Pittsburgh
- Study coordinator: Bochkis, Irina
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.